{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:11:24Z","timestamp":1767165084586,"version":"build-2238731810"},"reference-count":31,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify cardiovascular disease (CVD) preventive treatments combinations, among them and with other drugs, and to determine their prevalence in a cohort of Spanish workers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Aragon Workers\u2019 Health Study (AWHS) cohort in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>5577 workers belonging to AWHS cohort. From these subjects, we selected those that had, at least, three prescriptions of the same therapeutic subgroup in 2014 (n=4605).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Drug consumption was obtained from the Aragon Pharmaceutical Consumption Registry (Farmasalud). In order to know treatment utilisation, prevalence analyses were conducted. Frequent item set mining techniques were applied to identify drugs co-prescription patterns. All the results were stratified by sex and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>42.3% of men and 18.8% of women in the cohort received, at least, three prescriptions of a CVD preventive treatment in 2014. The most prescribed CVD treatment were antihypertensives (men: 28.2%, women 9.2%). The most frequent association observed among CVD preventive treatment was agents acting on the renin-angiotensin system and lipid-lowering drugs (5.1% of treated subjects). Co-prescription increased with age, especially after 50 years old, both in frequency and number of associations, and was higher in men. Regarding the association between CVD preventive treatments and other drugs, the most frequent pattern observed was lipid-lowering drugs and drugs used for acid related disorders (4.2% of treated subjects).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is an important number of co-prescription patterns that involve CVD preventive treatments. These patterns increase with age and are more frequent in men. Mining techniques are a useful tool to identify pharmacological patterns that are not evident in the individual clinical practice, in order to improve drug prescription appropriateness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-023571","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T07:45:45Z","timestamp":1555314345000},"page":"e023571","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker\u2019 health study (Spain)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-701X","authenticated-orcid":false,"given":"Isabel","family":"Aguilar-Palacio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aaJes\u00fas","family":"Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Feja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-5586","authenticated-orcid":false,"given":"Juan","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Moreno-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aaJos\u00e9","family":"Rabanaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,4,14]]},"reference":[{"key":"2020050713475979000_9.4.e023571.1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.recesp.2013.05.014","article-title":"Contributions of cardiovascular mortality to Spanish life expectancy from 1980 to 2009","volume":"66","author":"Garc\u00eda Gonz\u00e1lez","year":"2013","journal-title":"Rev Esp Cardiol"},{"key":"2020050713475979000_9.4.e023571.2","first-page":"389","article-title":"[Population analysis by area of health of changes in consumption, price and expenditure of cardiovascular drugs in eight autonomous communities, Spain, 2005]","volume":"84","author":"Sanf\u00e9lix-Gimeno","year":"2010","journal-title":"Rev Esp Salud Publica"},{"key":"2020050713475979000_9.4.e023571.3","unstructured":"Informe de utilizaci\u00f3n de medicamentos U\/HLP\/ V1\/17012014. Utilizaci\u00f3n de medicamentos hipolipemiantes en Espa\u00f1a durante el periodo 2000-2012. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, 2014. (accessed April 2018)."},{"key":"2020050713475979000_9.4.e023571.4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.recesp.2015.06.012","article-title":"Use of Antihypertensive Drugs in Spain: National Trends From 2000 to 2012","volume":"68","author":"Greciano","year":"2015","journal-title":"Rev Esp Cardiol"},{"key":"2020050713475979000_9.4.e023571.5","unstructured":"Informe de utilizaci\u00f3n de medicamentos U\/AN\/V1\/03092015. Utilizaci\u00f3n de medicamentos antidiab\u00e9ticos en Espa\u00f1a durante el periodo 2000-2014. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, 2014."},{"key":"2020050713475979000_9.4.e023571.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht407"},{"key":"2020050713475979000_9.4.e023571.7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-959300"},{"key":"2020050713475979000_9.4.e023571.8","doi-asserted-by":"crossref","unstructured":"Chao CT , Tsai HB , Wu CY , et al . Cumulative Cardiovascular Polypharmacy Is Associated With the Risk of Acute Kidney Injury in Elderly Patients. Medicine 2015;94:e1251.doi:10.1097\/MD.0000000000001251","DOI":"10.1097\/MD.0000000000001251"},{"key":"2020050713475979000_9.4.e023571.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00757.x"},{"key":"2020050713475979000_9.4.e023571.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-011-9710-5"},{"key":"2020050713475979000_9.4.e023571.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-12-45"},{"key":"2020050713475979000_9.4.e023571.12","unstructured":"ATCC\/DDD Index 2018. WHO collaborating Centre for Drug Statistics Methodology. http:\/\/www.whocc.no\/atc_ddd_index\/ (accesed Feb 2018)."},{"key":"2020050713475979000_9.4.e023571.13","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1074."},{"key":"2020050713475979000_9.4.e023571.14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1109\/69.846291","article-title":"Scalable algorithms for association mining","volume":"12","author":"Zaki","year":"2000","journal-title":"IEEE Trans Knowl Data Eng"},{"key":"2020050713475979000_9.4.e023571.15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0140-6736(14)62005-5","article-title":"Sex, statins, and statistics","volume":"385","author":"Mosca","year":"2015","journal-title":"Lancet"},{"key":"2020050713475979000_9.4.e023571.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht368"},{"key":"2020050713475979000_9.4.e023571.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02534.x"},{"key":"2020050713475979000_9.4.e023571.18","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2012.3972"},{"key":"2020050713475979000_9.4.e023571.19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.aprim.2013.09.003","article-title":"[Analysis of medications dispensed to control the main cardiovascular risks in the Murcia Region: are there gender differences?]","volume":"46","author":"S\u00e1nchez","year":"2014","journal-title":"Aten Primaria"},{"key":"2020050713475979000_9.4.e023571.20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1157\/13115104","article-title":"Gender influence in the quantity of drugs used in primary care","volume":"22","author":"Sanf\u00e9lix","year":"2008","journal-title":"Gac Sanit"},{"key":"2020050713475979000_9.4.e023571.21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.aprim.2013.06.004","article-title":"Population prevalence and control of cardiovascular risk factors: what electronic medical records tell us","volume":"46","author":"Catal\u00e1n-Ramos","year":"2014","journal-title":"Aten Primaria"},{"key":"2020050713475979000_9.4.e023571.22","doi-asserted-by":"crossref","unstructured":"Calder\u00f3n-Larra\u00f1aga A , Gimeno-Feliu LA , Gonz\u00e1lez-Rubio F , et al . Polypharmacy patterns: unravelling systematic associations between prescribed medications. PLoS One 2013;8:e84967.doi:10.1371\/journal.pone.0084967","DOI":"10.1371\/journal.pone.0084967"},{"key":"2020050713475979000_9.4.e023571.23"},{"key":"2020050713475979000_9.4.e023571.24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40266-017-0494-2","article-title":"Optimization of drug prescription and medication management in older adults with cardiovascular disease","volume":"34","author":"Wenger","year":"2017","journal-title":"Drugs Aging"},{"key":"2020050713475979000_9.4.e023571.25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bcp.12626","article-title":"Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study","volume":"80","author":"Warl\u00e9-van Herwaarden","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2020050713475979000_9.4.e023571.26","unstructured":"Groc B . Inhibidores de la bomba de protones: no son \u201cprotectores\u201d, son f\u00e1rmacos [Internet]. Fundaci\u00f3 Institut Catal\u00e0 de Farmacologia. Universitat Aut\u00f2noma de Barcelona. 2016:1\u20134 https:\/\/ddd.uab.cat\/record\/86197."},{"key":"2020050713475979000_9.4.e023571.27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.aprim.2015.10.006","article-title":"Patrones de multimorbilidad en adultos j\u00f3venes en Catalu\u00f1a: un an\u00e1lisis de cl\u00fasteres","volume":"48","author":"Viol\u00e1n","year":"2016","journal-title":"Atenci\u00f3n Primaria"},{"key":"2020050713475979000_9.4.e023571.28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3617"},{"key":"2020050713475979000_9.4.e023571.29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-12-70"},{"key":"2020050713475979000_9.4.e023571.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8525"},{"key":"2020050713475979000_9.4.e023571.31","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730070-00010"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2018-023571corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,26]],"date-time":"2020-01-26T00:00:00Z","timestamp":1579996800000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-023571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T23:32:30Z","timestamp":1601076750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-023571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bmjopen-2018-023571"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-023571","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}